靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
Clinical Trial Phase IIa, on Amelioration of Decompensated Liver Cirrhosis With Mesenchymal Stem Cells-derived Exosomes
Decompensated liver cirrhosis (LC), a life-threatening complication of chronic liver disease, is one of the major indications for liver transplantation. Recently, mesenchymal stem cell (MSC) transfusion has been shown to lead to the regression of liver fibrosis in mice and humans. However, little is known about MSC-exosome therapy. We will evaluate the therapeutic potential of mesenchymal stem Cell-Exosomes as an alternative to cell therapy in Cirrhotic patients. This study examined the safety and efficacy of umbilical cord-derived MSC-exosomes in patients with decompensated LC.
100 项与 Research Institute for Gastroenterology and Liver Diseases 相关的临床结果
0 项与 Research Institute for Gastroenterology and Liver Diseases 相关的专利(医药)
100 项与 Research Institute for Gastroenterology and Liver Diseases 相关的药物交易
100 项与 Research Institute for Gastroenterology and Liver Diseases 相关的转化医学